To determine the overall survival and gastrointestinal toxicity for patients treated with salvage definitive chemoradiotherapy after primary surgery for locoregional relapse of oesophageal carcinoma. A retrospective review of 525 patients who had a resection for oesophageal or oesophagogastric carcinoma at Princess Alexandra Hospital identified 14 patients treated with salvage definitive radiotherapy or chemo-radiotherapy, following localized recurrence of their disease. We analysed the patient and treatment characteristics to determine the median overall survival as the primary end point. Gastrointestinal toxicity was examined to determine if increased toxicity occurred when the stomach was irradiated within the intrathoracic radiotherapy field. The median overall survival for patients treated with curative intent using salvage definitive chemo-radiotherapy was 16 months and the 2-year overall survival is 21%. One patient is in clinical remission more than 5 years after therapy. Age ,60 years old and nodal recurrence were favourable prognostic factors. Treatment compliance was 93% with only one patient unable to complete the intended schedule. Fourteen per cent of patients experienced grade 3 or 4 gastrointestinal toxicity. Salvage definitive chemo-radiotherapy should be considered for good performance status patients with oesophageal carcinoma who have a locoregional relapse after primary surgery. The schedule is tolerable with low toxicity and an acceptable median survival.
INTRODUCTION
Carcinoma of the oesophagus is a rare disease in most countries although its incidence in the developed world is rising rapidly.
1 This is mainly because of an increase in adenocarcinoma, which typically arises in the distal oesophagus or gastro-oesophageal junction. The optimal management in terms of local control is surgical resection although local recurrence and the development of distant metastases remain a problem. For patients unable to have surgery, radical chemo-radiotherapy is an alternative, although its efficacy is most marked in squamous cell carcinomas and in the proximal two thirds of the oesophagus. 2 For tumours that are resectable, a recent meta-analysis clearly shows an improvement in outcomes with the use of both neoadjuvant chemotherapy and neoadjuvant chemo-radiotherapy. 2 Despite these efforts to improve results with neoadjuvant therapy, there are a proportion of patients who fail locoregionally without evidence of systemic metastasis. In these patients, there is a potential for cure, accepting that the risk of further distant relapse remains high.
For oesophageal tumours, the issue of salvage therapy in the event of locoregional recurrence is rarely considered. Head and neck cancer represents an example of where locoregional failures can possibly be salvaged by radiotherapy after initial surgery. 3 
Salvage treatment schedules

Radiation technique
Patients were planned using conformal three-dimensional CT planning and treated supine in a shell using a three-or fourfield, two-phase technique with lung inhomogeneity correction.
The gross tumour volume was covered with a margin of 2- 
End-points
Survival was determined from the date of initial diagnosis and from the diagnosis of the locoregional recurrence to death. cisplatin and 5FU were used in 36% of patients, while a single agent was used in 36%. One patient had excision of a supraclavicular lymph node followed by regional radiotherapy. These details are summarized in Table 2 .
Of the three patients who received neoadjuvant chemo- and site of recurrence (anastomotic recurrence) predicted for a poorer outcome. These results are shown in Table 3 .
Toxicity of salvage therapy was generally acceptable. The most notable side-effects were related to oesophagitis and gastritis with five patients experiencing this toxicity (one with grade 3 oesophagitis). These results are summarized in Table 4 .
There were no radiotherapy-related treatment breaks, with all 14 patients completing the course as intended. There were no toxicity-related hospital admissions or cases of pneumonitis in this cohort.
DISCUSSION
Data on the survival benefit of salvage chemo-radiotherapy for locoregional recurrent oesophageal cancer after initial surgery There have been other reported studies involving salvage radiation therapy for patients in this setting, usually with concurrent chemo-radiotherapy. The majority of these reports are from Japan, involving patients with squamous cell carcinomas. [4] [5] [6] [7] There are reports of a 2-year survival of 19% with a median survival of 9.5 and 13.8 months, respectively. Whether these adverse prognostic factors should be considered for more intensive treatment is unclear. We can only postulate that perhaps, anastomotic recurrences do worse than nodal recurrences because of the influence on the ability to eat and maintain adequate nutrition and a stable weight. Ideally, a prospective randomized controlled trial would be required to There was no inference from these data that gastric toxicity is increased with the presence of the stomach in the irradiated field within the thorax. There was a 15% (2 of 14) rate of grade 3 or 4 gastrointestinal toxicity presenting as nausea and heartburn. It is possible that a relative decrease in blood supply to the transposed stomach may result in less radiation damage and therefore explain these findings. In addition, conformal radiation fields may also contribute to the low toxicity observed. Despite having had previous therapy, we felt that the outcome in these patients was surprisingly good and that the principle of salvage radical chemo-radiotherapy is applicable to oesophageal cancer as it is in other forms of cancer.
CONCLUSION
We conclude that the median overall survival of 16 months for definitive salvage radiotherapy with or without chemotherapy is tolerable and that this approach is justifiable in this small group of highly selected patients. Age and site of recurrence appear to influence outcomes with statistical significance. There is no trend towards greater toxicity with the stomach being within the irradiated field within the thorax. 
